THE VALUE OF P53 AND KI67 AS MARKERS FOR TUMOR PROGRESSION IN THE BARRETTS DYSPLASIA-CARCINOMA SEQUENCE

被引：74

作者：

POLKOWSKI, W

VANLANSCHOT, JJB

TENKATE, FJW

BAAK, JPA

TYTGAT, GNJ

OBERTOP, H

VOORN, WJ

OFFERHAUS, GJA

机构：

[1] Department of Surgery, Academic Medical Center, University of Amsterdam, Amsterdam

[2] Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam

[3] Department of Gastroenterology, Academic Medical Center, University of Amsterdam, Amsterdam

[4] Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, Amsterdam

[5] Department of Pathology, Free University Hospital, Amsterdam

来源：

SURGICAL ONCOLOGY-OXFORD | 1995年 / 4卷 / 03期

关键词：

BARRETT; CARCINOMA; DYSPLASIA; KI67; ANTIBODY; P53; GENE;

D O I：

10.1016/S0960-7404(10)80021-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the Barrett's oesophagus (BE) progression from metaplasia, via dysplasia, into invasive cancer, an aberrant cell proliferation governed by genetic change plays a central role. Alterations of the p53 tumour-suppressor gene appear especially critical and, like the proliferation marker Ki67, can be detected by immunohistochemistry. The purpose of this study therefore was to investigate the clinical value of p53 and Ki67 as markers for tumour progression in BE, and at the same time test the validity of the concept of a metaplasia-dysplasia-carcinoma sequence in BE by correlating the expression of these markers with various grades of dysplasia. Thirty-two lesions (seven negative for dysplasia, five indefinite for dysplasia, 11 low-grade dysplasia and nine high-grade dysplasia) from 25 archival resection specimens were selected for study. Increasing grades of dysplasia showed increasingly p53 accumulation; p53 accumulation was never observed in mucosa without dysplasia. The increasing p53 expression was accompanied by an increased Ki67-labelling index and an upward shift of the proliferative compartment. The results lend support to the multistep progression model of a metaplasia-dysplasia-carcinoma sequence in BE. Expression of p53 and Ki67, markers which can be easily applied on archival material, can be valuable adjuncts for the histopathological diagnosis of dysplasia and may have predictive value for cancer risk.

引用

页码：163 / 171

页数：9

共 37 条

[31]

Ramel S, Reid BJ, Sanchez CA, Et al., Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry, Gastroenterology, 102, pp. 1220-1228, (1992)

[32]

Jankowski J, Coghill G, Hopwood D, Wormsley KG, Oncogenes and onco-suppressor genes in adenocarcinoma of the esophagus, Gut, 33, pp. 1033-1038, (1992)

[33]

Flejou JF, Potet F, Muzeau F, Le Pelletier F, Fekete F, Henin D, Overexpression of p53 protein in Barrett's syndrome with malignant transformation, Journal of Clinical Pathology, 46, pp. 330-333, (1993)

[34]

Younes M, Lebovitz RM, Lechago LV, Lechago J, p53-protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: a follow-up study, Gastroenterology, 105, pp. 1637-1642, (1993)

[35]

Casson AG, Manolopoulos B, Troster M, Et al., Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer, Am J Surg, 167, pp. 52-57, (1994)

[36]

Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D, Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence, Gut, 35, pp. 764-768, (1994)

[37]

Wesdorp ICE, Bartelsman J, Schipper MEI, Offerhaus J, Tytgat GNJ, Malignancy and premalignancy in Barrett's esophagus: a clinical, endoscopical and histological study, Acta Endosc, 11, pp. 317-326, (1981)

← 1 2 3 4 →